Abstract
Bisphosphonates are widely use for pathologies such as osteoporosis, Pagets disease or bone metastasis. However, their potent antiresorptive properties open new therapeutic opportunities for other conditions associated with an increased focal or systemic bone remodelling. Moreover, apart from their antiresorptive activity, bisphosphonates could also have others properties through a specific analgesic or anti-inflammatory effect. Thus, rheumatic diseases like rheumatoid arthritis, spondylarthritis or SAPHO syndrome (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) that are associated with systemic and sometimes focal bone loss could be good candidates for bisphosphonate therapy. Other non-inflammatory rheumatic diseases like bone osteonecrosis, algodystrophy, fibrous dysplasia or neuropathic osteoarthropathy are also associated with pain and an increase of focal bone remodelling. Several studies have shown that bisphosphonate could have promising therapeutic potential in these inflammatory or non-inflammatory diseases where therapeutic options are usually few. This review will focus on the new potential alternative indications for bisphosphonate in rheumatic diseases.
Keywords: Animals model, Bisphosphonates, Complex regional pain type I, Algodystrophy, Osteonecrosis, Osteoclast, Fibrous dysplasia, SAPHO, Aseptic osteitis, Charcot’s neuro-osteoarthropathy, Rheumatoid arthritis, Methotrexate, Zoledronic acid
Current Pharmaceutical Design
Title: Alternative Use of Bisphosphonate Therapy for Rheumatic Disease
Volume: 16 Issue: 27
Author(s): B. Le Goff, J.-M. Berthelot, Y. Maugars and E. Romas
Affiliation:
Keywords: Animals model, Bisphosphonates, Complex regional pain type I, Algodystrophy, Osteonecrosis, Osteoclast, Fibrous dysplasia, SAPHO, Aseptic osteitis, Charcot’s neuro-osteoarthropathy, Rheumatoid arthritis, Methotrexate, Zoledronic acid
Abstract: Bisphosphonates are widely use for pathologies such as osteoporosis, Pagets disease or bone metastasis. However, their potent antiresorptive properties open new therapeutic opportunities for other conditions associated with an increased focal or systemic bone remodelling. Moreover, apart from their antiresorptive activity, bisphosphonates could also have others properties through a specific analgesic or anti-inflammatory effect. Thus, rheumatic diseases like rheumatoid arthritis, spondylarthritis or SAPHO syndrome (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) that are associated with systemic and sometimes focal bone loss could be good candidates for bisphosphonate therapy. Other non-inflammatory rheumatic diseases like bone osteonecrosis, algodystrophy, fibrous dysplasia or neuropathic osteoarthropathy are also associated with pain and an increase of focal bone remodelling. Several studies have shown that bisphosphonate could have promising therapeutic potential in these inflammatory or non-inflammatory diseases where therapeutic options are usually few. This review will focus on the new potential alternative indications for bisphosphonate in rheumatic diseases.
Export Options
About this article
Cite this article as:
Le Goff B., Berthelot J.-M., Maugars Y. and Romas E., Alternative Use of Bisphosphonate Therapy for Rheumatic Disease, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563626
DOI https://dx.doi.org/10.2174/138161210793563626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety Taking Advantage of Viral Immune Evasion: Virus-Derived Proteins Represent Novel Biopharmaceuticals
Current Medicinal Chemistry Docking Studies for Multi-Target Drugs
Current Drug Targets Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging Sulphur-containing Amino Acids: Protective Role Against Free Radicals and Heavy Metals
Current Medicinal Chemistry Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Nongenomic Actions of Retinoids: Role of Nur77 and RXR in the Regulation of Apoptosis and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Approaches to Antidepressant Drug Design: Cytokine-Regulated Pathways
Current Pharmaceutical Design Editorial: [Hot Topic: Epigenetics in Arthritis]
Current Rheumatology Reviews Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Current Genomics Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling
Current Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Mucosal Adjuvants
Current Pharmaceutical Design Development of Yeast Molecular Display Systems Focused on Therapeutic Proteins, Enzymes, and Foods: Functional Analysis of Proteins and its Application to Bioconversion
Recent Patents on Biotechnology Current Treatments of Primary Sclerosing Cholangitis
Current Medicinal Chemistry Editorial [Hot Topic:Hemostatic Factors as Druggable Targets in Diverse Pathologies (Guest Editor: Susan A. McDowell)]
Current Pharmaceutical Biotechnology Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Current Pharmaceutical Design